Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gleevec and Low-Dose Ara-C in Elderly AML and High-Risk MDS
NCT00451997Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Mar 2004
- Primary completion
- Aug 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by University of Texas MD Anderson Cancer Center. Started Mar 2004; status: completed.
02
Drugs
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00451997.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00451997.